This study is looking at a new way to treat serious fungal infections in people with blood cancers. It's testing if adjusting the dose of an anti-fungal medicine called voriconazole based on your genes (pharmacogenomics) and special software can help more patients get the right amount of medicine in their body. This approach aims to make sure the voriconazole dose is just right for you. The study will compare this precision dosing to the usual way voriconazole is given. We want to see if this new method helps more patients reach the correct level of voriconazole by day 8 of treatment. This study is currently recruiting at least 104 children and adults. To join, you must be at least 2 years old, have a fungal infection, and be prescribed voriconazole. You cannot join if you recently had a certain type of stem cell transplant without prior DNA information, or if you are expected to pass away within 7 days.

Study design

This is an interventional study that will randomly assign participants to either receive standard care or precision care. At least 104 children and adults will participate.

What's involved

If you join, you will have blood samples taken on several days (Days 1, 2, 5, 9, 15, and 22) for genotype testing and to measure voriconazole levels. Your voriconazole dose may be adjusted based on these results.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured at Day 8, but blood sampling and dose adjustments continue until Day 22.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.